NASDAQ:CNSP CNS Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.27 +0.01 (+5.00%) (As of 07/7/2022 12:18 PM ET) Add Compare Share Today's Range$0.27▼$0.2750-Day Range$0.26▼$0.3552-Week Range$0.25▼$1.98Volume23,200 shsAverage Volume1.06 million shsMarket Capitalization$10.93 millionP/E RatioN/ADividend YieldN/APrice Target$2.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media CNS Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside822.5% Upside$2.50 Price TargetShort InterestHealthy0.71% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.51) to ($0.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.78 out of 5 starsMedical Sector749th out of 1,433 stocksPharmaceutical Preparations Industry376th out of 683 stocks 3.5 Analyst's Opinion Consensus RatingCNS Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.50, CNS Pharmaceuticals has a forecasted upside of 822.5% from its current price of $0.27.Amount of Analyst CoverageCNS Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.71% of the outstanding shares of CNS Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CNS Pharmaceuticals has recently decreased by 46.57%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCNS Pharmaceuticals does not currently pay a dividend.Dividend GrowthCNS Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CNSP. Previous Next 3.0 News and Social Media Coverage News SentimentCNS Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for CNS Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for CNSP on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CNS Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.60% of the stock of CNS Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 2.94% of the stock of CNS Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CNS Pharmaceuticals are expected to grow in the coming year, from ($0.51) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CNS Pharmaceuticals is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CNS Pharmaceuticals is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCNS Pharmaceuticals has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CNSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CNS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About CNS Pharmaceuticals (NASDAQ:CNSP) StockCNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.Read More CNSP Stock News HeadlinesJuly 1, 2022 | americanbankingnews.comCNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Down 46.6% in JuneJune 23, 2022 | seekingalpha.comCNS Pharma rises 36% as U.S. FDA gives nod for deadly brain cancer therapy trialJune 23, 2022 | finance.yahoo.comCNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBMJune 15, 2022 | americanbankingnews.comCNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Sees Significant Increase in Short InterestJune 8, 2022 | finance.yahoo.comCNS Pharmaceuticals Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual MeetingMay 24, 2022 | finance.yahoo.comCNS Pharmaceuticals Announces Presentation at the H.C. Wainwright Global Investment ConferenceMay 19, 2022 | finance.yahoo.comCNS Pharmaceuticals to Present at American Society of Clinical Oncology MeetingMay 18, 2022 | finance.yahoo.comCNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual MeetingMay 16, 2022 | finance.yahoo.comCNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateApril 28, 2022 | seekingalpha.comCNS Pharmaceuticals gets Spanish regulatory nod for brain cancer studyApril 28, 2022 | finance.yahoo.comCNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)April 12, 2022 | finance.yahoo.comCNS Pharmaceuticals to Participate in the Virtual Investor Glioblastoma Multiforme (GBM) Spotlight EventApril 8, 2022 | seekingalpha.comCNS Pharmaceuticals gets French regulatory nod for brain cancer studyApril 6, 2022 | finance.yahoo.comCNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)April 5, 2022 | benzinga.comCNS Pharmaceuticals (NASDAQ: CNSP) CEO Shares Company Highlights At Virtual Growth ConferenceApril 5, 2022 | baystreet.caCNS Pharmaceutical Wins Approval From SwissMarch 23, 2022 | finance.yahoo.comCNS Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-VestMarch 9, 2022 | finance.yahoo.comCNS Pharmaceuticals Reiterates Operational Progress and Addresses Recent Share Price Activity in Video to ShareholdersMarch 8, 2022 | benzinga.comCNS Pharmaceuticals Gives Corporate Presentation, Q&A SessionMarch 3, 2022 | finance.yahoo.comCNS Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate UpdateFebruary 1, 2022 | finance.yahoo.comWPD Pharmaceuticals Secures Berubicin Sub-License Rights in PerpetuityJanuary 20, 2022 | finance.yahoo.comCNS Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks ConferenceJanuary 20, 2022 | finance.yahoo.comIs CNS Pharmaceuticals, Inc. (CNSP) Outperforming Other Medical Stocks This Year?January 11, 2022 | benzinga.comCNS Pharmaceuticals Closes on $11.5M Private PlacementJanuary 10, 2022 | finance.yahoo.comCNS Pharmaceuticals Announces Closing of $11.5 Million Private Placement Priced At-the-Market Under Nasdaq RulesSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CNSP CUSIPN/A CIK1729427 Webwww.cnspharma.com Phone800-946-9185FaxN/AEmployees3Year FoundedN/ACompany Calendar Last Earnings8/12/2021Today7/07/2022Next Earnings (Estimated)8/12/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$2.50 High Stock Price Forecast$4.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+815.8%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-123.05% Return on Assets-104.87% Debt Debt-to-Equity RatioN/A Current Ratio13.78 Quick Ratio13.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / Book1.14Miscellaneous Outstanding Shares40,030,000Free Float36,589,000Market Cap$10.93 million OptionableNot Optionable Beta1.67 CNS Pharmaceuticals Frequently Asked Questions Should I buy or sell CNS Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CNS Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CNS Pharmaceuticals stock. View analyst ratings for CNS Pharmaceuticals or view top-rated stocks. What is CNS Pharmaceuticals' stock price forecast for 2022? 1 brokerages have issued 12 month target prices for CNS Pharmaceuticals' stock. Their CNSP stock forecasts range from $1.00 to $4.00. On average, they expect CNS Pharmaceuticals' share price to reach $2.50 in the next year. This suggests a possible upside of 815.8% from the stock's current price. View analysts' price targets for CNS Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has CNS Pharmaceuticals' stock performed in 2022? CNS Pharmaceuticals' stock was trading at $0.7024 on January 1st, 2022. Since then, CNSP stock has decreased by 61.1% and is now trading at $0.2730. View the best growth stocks for 2022 here. When is CNS Pharmaceuticals' next earnings date? CNS Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for CNS Pharmaceuticals. How were CNS Pharmaceuticals' earnings last quarter? CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) released its quarterly earnings results on Thursday, August, 12th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.01. View CNS Pharmaceuticals' earnings history. Who are CNS Pharmaceuticals' key executives? CNS Pharmaceuticals' management team includes the following people: Mr. John Michael Climaco Esq., J.D., Chairman, CEO & Pres (Age 53, Pay $648k)Mr. Christopher S. Downs CPA, CTP, FP&A, Chief Financial Officer (Age 44, Pay $398k)Dr. Sandra L. Silberman M.D., Ph.D., Chief Medical Officer (Age 67, Pay $228k)Dr. Waldemar Priebe Ph.D., Founder & Chairman of the Scientific Advisory BoardDr. Donald H. Picker Ph.D., Chief Science Officer (Age 76) Who are some of CNS Pharmaceuticals' key competitors? Some companies that are related to CNS Pharmaceuticals include Neoleukin Therapeutics (NLTX), Flora Growth (FLGC), Oragenics (OGEN), Oragenics (OGEN), Aptinyx (APTX), Spruce Biosciences (SPRB), BioVie (BIVI), Longboard Pharmaceuticals (LBPH), Eledon Pharmaceuticals (ELDN), Iterum Therapeutics (ITRM), Purple Biotech (PPBT), Societal CDMO (SCTL), Chemomab Therapeutics (CMMB), Cocrystal Pharma (COCP) and PhaseBio Pharmaceuticals (PHAS). View all of CNSP's competitors. What other stocks do shareholders of CNS Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other CNS Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Advanced Micro Devices (AMD), Heat Biologics (HTBX), Roku (ROKU), Aldeyra Therapeutics (ALDX), Salesforce (CRM), Gilead Sciences (GILD), Inseego (INSG), Nokia Oyj (NOK) and Square (SQ). When did CNS Pharmaceuticals IPO? (CNSP) raised $9 million in an initial public offering on Friday, November 8th 2019. The company issued 2,100,000 shares at $4.00-$5.00 per share. Benchmark served as the underwriter for the IPO. What is CNS Pharmaceuticals' stock symbol? CNS Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNSP." How do I buy shares of CNS Pharmaceuticals? Shares of CNSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CNS Pharmaceuticals' stock price today? One share of CNSP stock can currently be purchased for approximately $0.27. How much money does CNS Pharmaceuticals make? CNS Pharmaceuticals (NASDAQ:CNSP) has a market capitalization of $10.93 million. The company earns $-14,040,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. How many employees does CNS Pharmaceuticals have? CNS Pharmaceuticals employs 3 workers across the globe. How can I contact CNS Pharmaceuticals? CNS Pharmaceuticals' mailing address is 2100 WEST LOOP SOUTH SUITE 900, HOUSTON TX, 77027. The official website for CNS Pharmaceuticals is www.cnspharma.com. The company can be reached via phone at 800-946-9185 or via email at ir@cnspharma.com. This page (NASDAQ:CNSP) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
